

# Revascularization

## *Bibliography of One Hundred Key Papers*

selected by **James T. Willerson\***, MD; **L. Maximilian Buja†**, MD

*\*President, The University of Texas Health Science Center (UTHSC) at Houston  
President-Elect and Medical Director - Texas Heart Institute - Houston, Tex*

*† Executive Vice President for Academic Affairs - Professor of Pathology and Laboratory Medicine at the  
University of Texas Health Science Center (UTHSC) at Houston - Office of Academic Affairs -  
Chief, Cardiovascular Pathology - Texas Heart Institute - Houston, Tex - USA*

- 
- Apprill P, Schmitz JM, Campbell WB, et al.** *Cyclic blood flow variations induced by platelet activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and alpha-adrenergic receptors.*  
**Circulation.** 1985;72:397-405.
- 
- Ashton JH, Benedict CR, Fitzgerald C, et al.** *Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries.*  
**Circulation.** 1986;73:572-578.
- 
- Ashton JH, Schmitz JM, Campbell WB, et al.** *Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A<sub>2</sub>/prostaglandin H<sub>2</sub> antagonists.*  
**Circ Res.** 1986;59:568-578.
- 
- Auchampach JA, Grover CJ, Gross GJ.** *Blockade of ischemic preconditioning of dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate.*  
**Cardiovasc Res.** 1992;26:1054-1062.
- 
- Basuk WL, Reimer KA, Jennings RB.** *Effect of repetitive brief episodes of ischemia on cell volume, electrolytes and ultrastructure.*  
**J Am Coll Cardiol.** 1986;8(suppl):33A-41A.
- 
- Blankenberg FG, Katsikis PD, Tait JF, et al.** *In vivo detection and imaging of phosphatidylserine expression during programmed cell death.*  
**Proc Natl Acad Sci U S A.** 1998;95:6349-6354.
- 
- Bolli R.** *Myocardial "stunning" in man.*  
**Circulation.** 1992;86:1671-1691.
- 
- Bolli R, Jeroudi MO, Patel BS, et al.** *Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog.*  
**Proc Natl Acad Sci U S A.** 1989;86:4695-4699.
- 
- Bolli R, Jeroudi MO, Patel BS, et al.** *Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion: evidence that myocardial "stunning" is a manifestation of reperfusion injury.*  
**Circ Res.** 1989;65:607-622.
- 
- Bolli R, Patel BS, Jeroudi MO, et al.** *Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap alpha-phenyl N-tertiary butyl nitron.*  
**J Clin Invest.** 1988;82:476-485.
-

**Bibliography of One Hundred Key Papers**

---

- Bolli R, Patel BS, Zhu WX, et al.** *The iron chelator desferrioxamine attenuated postischemic ventricular dysfunction.*  
**Am J Physiol.** 1987;253:H1372-H1380.
- 
- Bolli R, Zhu WX, Thornby JL, et al.** *Time-course and determinants of recovery of function after reversible ischemia in conscious dogs.*  
**Am J Physiol.** 1988;254:H102-H114.
- 
- Braunwald E, Kloner RA.** *The stunned myocardium: prolonged, post-ischemic ventricular dysfunction.*  
**Circulation.** 1982;66:1146-1149.
- 
- Buja LM.** *Myocardial ischemia and reperfusion injury.*  
**Cardiovasc Pathol.** 2005;14:170-175.
- 
- Bush LR, Buja LM, Tilton G, et al.** *Effects of propranolol and diltiazem alone and in combination on the recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs.*  
**Circulation.** 1985;72:413-430.
- 
- Bush LR, Campbell WB, Kern K, et al.** *The effects of alpha<sub>2</sub> adrenergic and serotonergic receptor blockade on platelet aggregation in stenosed canine coronary arteries.*  
**Circ Res.** 1984;55:642-652.
- 
- Bush LR, Campbell WB, Tilton GD, Buja LM, Willerson JT.** *Effects of the selective thromboxane synthetase inhibitor, dazoxiben, on cyclic flow variations in stenosed canine coronary arteries.*  
**Trans Assoc Am Physicians.** 1983;96:103-112.
- 
- Carlson EB, Hinohara T, Morris K.** *Recovery of systolic and diastolic left ventricular function after a 60-second coronary arterial occlusion during percutaneous transluminal coronary angioplasty for angina pectoris.*  
**Am J Cardiol.** 1987;60:460-466.
- 
- Casthly PA, Shah C, Merhjian H, et al.** *Left ventricular diastolic function after coronary artery bypass grafting. A correlative study with three different myocardial protection techniques.*  
**J Thorac Cardiovasc Surg.** 1997;114:254-260.
- 
- Chou WH, Choi DS, Zhang H, et al.** *Neutrophil protein kinase C delta as a mediator of stroke-reperfusion injury.*  
**J Clin Invest.** 2004;114:49-56.
- 
- Cohen MV, Baines CP, Downey JM.** *Ischemic preconditioning from adenosine receptor to K<sub>ATP</sub> channel.*  
**Annu Rev Physiol.** 2000;62:79-109.
- 
- Cohen MV, Yang XM, Downey JM.** *Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning.*  
**Circ Res.** 1994;74:998-1004.
- 
- Diamond GA, Forrester JS, de Luz PL, et al.** *Post-extrasystolic potentiation of ischemic myocardium by atrial stimulation.*  
**Am Heart J.** 1978;95:204-209.
- 
- Downey JM, Cohen MV.** *Mitochondrial K<sub>ATP</sub> channel opening during index ischemia and following myocardial reperfusion in ischemic rat hearts.*  
**J Mol Cell Cardiol.** 2001;33:651-653.
-



- 
- Downey JM, Yellon DM.** *The biology of preconditioning. In: Heyndrickx GR, Vatner SF, Wijns W, eds. **Stunning, Hibernation and Preconditioning: Clinical Pathophysiology of Myocardial Ischemia.** Philadelphia, Pa: Lippincott-Raven Publishers; 1997:105-119.*
- 
- Duranski MR, Greer JJ, Dejam A, et al.** *Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. **J Clin Invest.** 2005;115:1232-1240.*
- 
- Eidt JF, Allison P, Noble S, et al.** *Thrombin is an important mediator of platelet aggregation in stenosed and endothelially injured canine coronary arteries. **J Clin Invest.** 1989;84:18-27.*
- 
- Elsässer A, Vogt AM, Nef H, et al.** *Human hibernating myocardium is jeopardized by apoptotic and autophagic cell death. **J Am Coll Cardiol.** 2004;43:2191-2199.*
- 
- Farber NE, Vercellotti GM, Jacob HS, et al.** *Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in canine heart. **Circ Res.** 1988;63:351-360.*
- 
- Ferreire R, Burgos M, Lirsui S, et al.** *Reduction of reperfusion injury with mannitol cardioplegia. **Ann Thorac Surg.** 1989;48:77-83.*
- 
- Folts J.** *An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. **Circulation.** 1991;83:IV3-IV14.*
- 
- Folts JD, Rowe GG.** *Cyclic reductions in coronary blood flow in coronary arteries with fixed partial obstruction and their inhibition by aspirin. **Fed Proc.** 1974;33:413.*
- 
- Foo RS, Mani K, Kitsis RN.** *Death begets failure in the heart. **J Clin Invest.** 2005;115:565-571.*
- 
- Forman MB, Virmani R, Puett DW.** *Mechanisms and therapy of myocardial reperfusion injury. **Circulation.** 1990;81(suppl IV):IV69-IV78.*
- 
- Fryer RM, Hsu AK, Gross GJ.** *Mitochondrial  $K_{ATP}$  channel opening is important during index ischemia and following myocardial reperfusion in ischemic preconditioned rat hearts. **J Mol Cell Cardiol.** 2001;33:831-834.*
- 
- Fujita T, Asai T, Andrassy M, et al.** *PKC beta regulates ischemia/reperfusion injury in the lung. **J Clin Invest.** 2004;113:1615-1623.*
- 
- Gao WD, Atar D, Liu Y, et al.** *Role of troponin I proteolysis in the pathogenesis of stunned myocardium. **Circ Res.** 1997;80:393-399.*
- 
- Garg S, Hofstra L, Reutelingsperger C, Narula J.** *Apoptosis as a therapeutic target in acutely ischemic myocardium. **Curr Opin Cardiol.** 2003;18:372-377.*
-

**Bibliography of One Hundred Key Papers**

- 
- Garlid KD, Paucek P, Yarov-Yarovoy V, et al.** *Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K<sup>+</sup> channels.*  
**Circ Res.** 1997;81:1072-1082.
- 
- Golino P, Ashton JH, Buja LM, et al.** *Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo: thromboxane A<sub>2</sub> and serotonin are possible mediators.*  
**Circulation.** 1989;79:154-166.
- 
- Gross GJ, Farber NE, Hardman HF, et al.** *Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs.*  
**Am J Physiol.** 1986;250:H372-H377.
- 
- Grover GJ, Slep PG, Dzwonczyk S.** *Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A<sub>1</sub>-receptors.*  
**Circulation.** 1992;86:1310-1316.
- 
- Hearse DJ, Bolli R.** *Reperfusion induced injury: manifestations, mechanisms, and clinical relevance.*  
**Cardiovasc Res.** 1992;26:101-108.
- 
- Heyndrickx GR, Baig H, Nellens P, et al.** *Depression of regional blood flow and wall thickening after brief coronary occlusions.*  
**Am J Physiol.** 1978;234:H653-H659.
- 
- Heyndrickx GR, Millard RW, McRitchie RJ, et al.** *Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs.*  
**J Clin Invest.** 1975;56:978-985.
- 
- Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT.** *Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.*  
**N Engl J Med.** 1981;304:685-691.
- 
- Jennings RB, Reimer KA.** *Discovery and early history of preconditioning. In: Heyndrickx GR, Vatner S, Wijns W, eds. **Stunning, Hibernation, and Preconditioning: Clinical Pathophysiology of Myocardial Ischemia.** Philadelphia, Pa: Lippincott-Raven Publisher; 1997:83-104.*
- 
- Jennings RB, Reimer KA, Hill ML, et al.** *Total ischemia in dog hearts, in vitro, I: comparison of high energy phosphate production, utilization and depletion and of adenine nucleotide catabolism in total ischemia in vitro versus severe ischemia in vivo.*  
**Circ Res.** 1981;49:489-900.
- 
- Jennings RB, Sebbag L, Schwartz LM, et al.** *Metabolism of preconditioned myocardium: effect of loss and reinstatement of cardioprotection.*  
**J Mol Cell Cardiol.** 2001;33:1571-1588.
- 
- Johnson SM, Mauritsen DR, Willerson JT, Hillis LD.** *A controlled trial of verapamil for Prinzmetal's variant angina.*  
**N Engl J Med.** 1981;304:362.
- 
- Jugdutt BI, Idikio HA.** *Apoptosis and oncosis in acute coronary syndromes: assessment and implications.*  
**Mol Cell Biochem.** 2005;270:277-200.
- 
- Kloner RA, Bolli R, Marban E, et al.** *Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI Workshop.*  
**Circulation.** 1998;97:1848-1867.
-



- 
- Kloner RA, Ellis SG, Lange R, et al.** *Studies of experimental coronary artery reperfusion: effects on infarct size, myocardial function, biochemistry, ultrastructure and micro-vascular damage.*  
**Circulation.** 1983;68(suppl I):II-115.
- 
- Kloner RA, Ganote CE, Jennings RB.** *The no reflow phenomenon after temporary coronary occlusion in the dog.*  
**J Clin Invest.** 1974;54:1496-1508.
- 
- Kloner RA, Jennings RB.** *Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: Part I.*  
**Circulation.** 2001;104:2981-2989.
- 
- Kloner RA, Jennings RB.** *Consequences of brief ischemia: stunning, preconditioning and their clinical implications: Part 2.*  
**Circulation.** 2001;104:3158-3167.
- 
- Kostin S.** *Pathways of myocyte death: implications for development of clinical laboratory biomarkers.*  
**Adv Clin Chem.** 2005;40:37-98.
- 
- Kuzuya T, Hoshida S, Yamashita N, et al.** *Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia.*  
**Circ Res.** 1993;72:1293-1299.
- 
- Liu GS, Thornton J, VanWinkle DM, et al.** *Protection against infarction afforded by preconditioning is mediated by A<sub>1</sub> adenosine receptors in rabbit heart.*  
**Circulation.** 1991;84:350-356.
- 
- Masaki M, Izumi M, Oshima Y, et al.** *Smad1 protects cardiomyocytes from ischemia-reperfusion injury.*  
**Circulation.** 2005;111:2752-2759.
- 
- Maxwell SR, Lip GY.** *Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options.*  
**Int J Cardiol.** 1997;58:95-117.
- 
- McDonough JL, Arrell DK, Van Eyk JE.** *Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury.*  
**Circ Res.** 1999;84:122-124.
- 
- Miura T, Goto M, Urabe K, et al.** *Does myocardial stunning contribute to infarct size limitation by ischemic preconditioning?*  
**Circulation.** 1991;84:2504-2512.
- 
- Moens AL, Claeys MJ, Timmermans JP, Vrints CJ.** *Myocardial ischemia/reperfusion-injury; a clinical view on a complex pathophysiological process.*  
**Int J Cardiol.** 2005;100:179-190.
- 
- Muller JE, Gunther SJ.** *Nifedipine therapy for Prinzmetal's angina.*  
**Circulation.** 1978;57:137.
- 
- Murry CE, Jennings RB, Reimer KA.** *Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.*  
**Circulation.** 1986;14:1124-1136.
- 
- Murry CE, Richard VJ, Jennings RB, et al.** *Myocardial protection is lost before contractile function recovers from ischemic preconditioning.*  
**Am J Physiol.** 1991;260:H796-H804.
-

**Bibliography of One Hundred Key Papers**

---

- Murry CE, Richard VJ, Reimer KA, et al.** *Ischemic preconditioning slows energy metabolism and delays ultra-structural damage during a sustained ischemic episode.*  
**Circ Res.** 1990;66:913-931.
- 
- Myers ML, Bolli R, Lekich RF, et al.** *Enhancement of recovery of myocardial function by oxygen free-radical scavengers after reversible regional ischemia.*  
**Circulation.** 1985;72:915-921.
- 
- Park JL, Lucchesi BR.** *Mechanisms of myocardial reperfusion injury.*  
**Ann Thorac Surg.** 1999;68:1905-1912.
- 
- Ping P, Zhang J, Qui Y, et al.** *Ischemic preconditioning induces selective translocation of PKC isoforms  $\epsilon$  and  $\eta$  in the hearts of conscious rabbits without subcellular redistribution of total PKC activity.*  
**Circ Res.** 1997;81:404-414.
- 
- Ping P, Zhang J, Zheng YT, et al.** *Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits.*  
**Circ Res.** 1999;85:542-550.
- 
- Przyklenk K, Kloner RA.** *Superoxide dismutase plus catalase improve contractile function in the canine model of the "stunned myocardium."*  
**Circ Res.** 1986;58:148-156.
- 
- Puskas JD, Vinten-Johansen J, Muraki S, Gyton R.** *Myocardial protection for off pump coronary artery bypass surgery.*  
**Sem Thorac Cardiovasc Surg.** 2001;13:81-88.
- 
- Rahimtoola SH.** *The hibernating myocardium.*  
**Am Heart J.** 1989;117:211-221.
- 
- Reimer K, Hill ML, Jennings RB.** *Prolonged depletion of ATP and of the adenine nucleotides pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs.*  
**J Mol Cell Cardiol.** 1981;13:229-239.
- 
- Reimer KA, Jennings RB.** *The "wavefront phenomenon" of myocardial ischemic cell death: II Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow.*  
**Lab Invest.** 1979;40:633-644.
- 
- Riksen NP, Oyen WJG, Ramakers BP, et al.** *Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.*  
**Clin Pharmacol Ther.** 2005;78:52-59.
- 
- Schmitz JM, Apprill PG, Buja LM, Willerson JT, Campbell WB.** *Vascular prostaglandin and thromboxane production in a canine model of myocardial ischemia.*  
**Circ Res.** 1985;57:223-231.
- 
- Sun DQ, Nguyen N, DeGrado TR, et al.** *Ischemia induces translocation of the insulin-responsive glucose transporter GLUT 4 to the plasma membrane of cardiac myocytes.*  
**Circulation.** 1994;89:793-798.
- 
- Sun Y, Jin K, Xie L, et al.** *VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia.*  
**J Clin Invest.** 2003;111:1843-1851.
-



- 
- Takano H, Bolli R, Black RG, et al.** *A<sub>1</sub> or A<sub>3</sub> adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms.*  
**Circ Res.** 2001;88:520-528.
- 
- Tillisch J, Brunken R, Marshall R, et al.** *Reversibility of cardiac wall motion abnormalities predicted by positron emission tomography.*  
**N Engl J Med.** 1986;314:884-888.
- 
- Vahlhaus C, Schulz R, Post H, et al.** *No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine.*  
**Circ Res.** 1996;79:407-414.
- 
- van den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ.** *Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology.*  
**Circulation.** 1989;79:116-124.
- 
- Weiss RG, de Albuquerque CP, Vandegaer K, et al.** *Attenuated glycogenolysis reduces glycolytic catabolite accumulation during ischemia in preconditioned rat hearts.*  
**Circ Res.** 1996;79:435-446.
- 
- Wijns W, Vatner SF, Camici PG.** *Hibernating myocardium.*  
**N Engl J Med.** 1998;339:173-181.
- 
- Willerson JT, Campbell WB, Winniford MD, et al.** *Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms (editorial).*  
**Am J Cardiol.** 1984;54:1349-1357.
- 
- Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM.** *Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications.*  
**Circulation.** 1989;80:198-205.
- 
- Willerson JT, Parkey RW, Bonte FJ, Lewis SE, Corbett J, Buja LM.** *Pathophysiologic considerations and clinicopathological correlates of technetium-99m stannous pyrophosphate myocardial scintigraphy.*  
**Sem Nucl Med.** 1980;10:54-69.
- 
- Willerson JT, Scales F, Mukherjee A, et al.** *Abnormal myocardial fluid retention as an early manifestation of ischemic injury.*  
**Am J Pathol.** 1977;87:159-188.
- 
- Willerson JT, Watson JT, Hutton I, Templeton GH, Fixler DE.** *Reduced myocardial reflow and increased coronary vascular resistance following prolonged myocardial ischemia in the dog.*  
**Circ Res.** 1975;36:771-781.
- 
- Xiao CY, Yuhki K, Hara A, et al.** *Prostaglandin E<sub>2</sub> protects the heart from ischemia-reperfusion injury via its receptor subtype EP 4.*  
**Circulation.** 2004;109:2462-2468.
- 
- Yang Z, Zingarelli B, Szabo C.** *Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury.*  
**Circulation.** 2000;101:1019-1026.
- 
- Yao SK, Ober JC, Gonenne A, et al.** *Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries.*  
**Circ Res.** 1993;73:952-967.
-

**Bibliography of One Hundred Key Papers**

**Yao SK, Ober JC, McNatt J, et al.**

*ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.*

**Circ Res.** 1992;70:39-48.

---

**Yao Z, Cavero I, Gross GJ.**

*Activation of cardiac  $K_{ATP}$  channels: an endogenous protective mechanism during repetitive ischemia.*

**Am J Physiol.** 1993;264:H495-H504.

---

**Yellon DM, Baxter GF.**

*A second window of protection or delayed protection preconditioning phenomenon: future horizons for myocardial protection?*

**J Mol Cell Cardiol.** 1995;27:1023-1034.

---

**Yellon DM, Downey JM.**

*Preconditioning the myocardium: from cellular physiology to clinical cardiology.*

**Physiol Rev.** 2003; 83:1113-1151.

---

---

# Instructions for authors

## GENERAL INSTRUCTIONS

---

- Manuscripts should be provided on word-processor disks (3.5-in, for IBM, IBM-compatible, or Apple computers) with three hard copies (text and figures) printed on one side of standard-sized white bond paper, double-spaced, with 2.5-cm margins. Pages must be numbered. **Standard typed page = 25 lines of 75 characters (including spaces) double-spaced, 2.5-cm margins = a total of 275 words per page.**
- All texts should be submitted in English. In the case of translations, the text in the original language should be included.
- On the **title page**, provide title of manuscript (title should be concise, not exceeding 120 characters, including spaces), **short running title**, **keywords**, and **acknowledgments**, as well as **full names** (first name, middle name(s), and last name) with **highest academic degrees** (in country-of-origin language), affiliations/address, telephone No., fax No., and E-mail address.
- **Illustrations** (photographs, tables, graphs, figures—high-quality printouts, glossy prints, and/or high-quality scans as jpg files) should be of good quality or professionally prepared, numbered according to their order, with proper orientation indicated (eg, “top,” or “left”), and **SHORT legends** provided, not repetitive of text. As figures and graphs may need to be reduced or enlarged, all absolute values and statistics should be provided. All **illustrations should be cited** in the text, with distinct numbering for figures and tables. Illustrations will be reproduced in full color only when clearly necessary, eg, images from nuclear medicine or histology.
- Include **HEADINGS** using a consistent style for the various levels of headings, to highlight key points and facilitate comprehension of the text. The Publisher reserves the right to add or delete headings when necessary.
- **Abbreviations** should be used sparingly and expanded at first mention.
- Use **Système International** (SI) units.
- Use **generic names of drugs**.
- All **references** should be cited in the text and **numbered consecutively using superscript arabic numerals**. The author-date system of citation is **NOT** acceptable. “In press” references are to be avoided. In the **bibliography**, titles of journals should be **abbreviated according to the Index Medicus**. All authors should be listed up to six; if there are more, only the first three should be listed, followed by “et al” (*Uniform requirements for manuscripts submitted to biomedical journals*: see www.icmje.org). Where necessary, references will be styled to *Dialogues in Cardiovascular Medicine* copyediting requirements. Authors bear total responsibility for the accuracy and completeness of all references and for correct text citation. Example of style for references:
  1. Ouriel K, Geary K, Green RM, Geary JE, DeWeese JA. Factors determining survival after ruptured abdominal aneurysm. *J Vasc Surg*. 1990;11:493-496.
  2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms: the case for early resection. *Circulation*. 1977;56(suppl II):II161-II164.
  3. Schulman JL. Immunology of influenza. In: Kilbourne ED, Alfade RT, eds. *The Influenza Viruses and Influenza*. Orlando, Fla: Academic Press Inc; 1975:373-393.
- **Copyediting**: all contributions to *Dialogues in Cardiovascular Medicine* will be styled by the Publisher’s editorial department according to the specifications of the current edition of the *American Medical Association Manual of Style*, Williams & Wilkins. Page proofs will be sent to authors for approval and should be returned within 5 days. If this time is exceeded, changes made by the editorial department will be assumed to be accepted by the author. Authors are responsible for all statements made in their work, including changes made by the editorial department and authorized by the author. The Publisher will edit Editorials, Abstracts, and Seminal Paper Summaries to required size if their length does not comply with specific requirements.
- **Copyright** of articles will be transferred to the Publisher of *Dialogues in Cardiovascular Medicine*. For reproduction

of existing work, it is the author’s responsibility to obtain copyright from the author(s) (including self) and the publisher(s) and provide copies of these authorizations with the manuscript.

## LEAD ARTICLE

---

The lead article should not exceed 30 standard typed pages (7000 to 8000 words), including an abstract of no more than 200 words, no more than 50 references, and a minimum of 5 - maximum of 10 illustrations (figures and/or tables). A maximum of 5-10 keywords should be included. **The 3 questions for the respondents should be introduced in or after the conclusion.** A separate list of “**10 references of seminal papers**” as well as a separate list of “**100 Key References**” should be provided.

## RESPONDENT ARTICLES

---

Respondent articles should not exceed 15 standard typed pages (3000 to 4000 words), including an abstract of no more than 125 words, no more than 10 references, and a minimum of 3 - maximum of 5 illustrations (figures and tables). A maximum of 5-10 keywords should be included.

## SEMINAL PAPER SUMMARIES

---

Seminal paper summaries take up one page of *Dialogues in Cardiovascular Medicine*: the length of each summary should **IMPERATIVELY** be comprised between 500 and 600 words, ie, **not exceed 3000 characters**. Summaries that are too short or too long will be returned to the author or edited by the Publisher. No figures, tables or references should be included in seminal paper summaries.

## FASCINOMA CARDIOLOGICA ARTICLES

---

Fascinoma Cardiologica articles (*A Lexicon of the Heart; Icons of Cardiology; Plants and the Heart; Trails of Discovery, etc*) should not exceed 2000 words (8 standard typed pages), should include 3 to 5 illustrations (figures and tables), and cite no more than 15 references. A maximum of 5-10 keywords should be included. No abstract.